News
Zacks Investment Research on MSN20d
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. The multi-year deal focuses on building a multimodal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback